Back to Search Start Over

Superior Identification of Metastatic Lesions by 68 Ga-FAPI-46 to 18 F-FDG PET/CT in a Case of SMARCA4-Deficient Undifferentiated Carcinoma of Stomach.

Authors :
Pang Y
Cai J
Zhao L
Xu W
Chen H
Source :
Clinical nuclear medicine [Clin Nucl Med] 2023 Nov 01; Vol. 48 (11), pp. 1009-1011. Date of Electronic Publication: 2023 Sep 12.
Publication Year :
2023

Abstract

Abstract: SMARCA4-deficient undifferentiated carcinoma is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. In this case, we reported 18 F-FDG and 68 Ga-FAPI-46 PET/CT imaging findings in a patient with SMARCA4-deficient undifferentiated carcinoma of stomach. 68 Ga-FAPI-46 PET/CT showed much higher tumor-to-background contrast of primary tumor and revealed more metastatic lesions than 18 F-FDG PET/CT. This case demonstrated the superiority of 68 Ga-FAPI PET/CT over 18 F-FDG for identifying both primary and metastatic lesions in SMARCA4-deficient undifferentiated carcinoma. This observation may add the information on the benefit of FAPI PET in oncology imaging.<br /> (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1536-0229
Volume :
48
Issue :
11
Database :
MEDLINE
Journal :
Clinical nuclear medicine
Publication Type :
Academic Journal
Accession number :
37703493
Full Text :
https://doi.org/10.1097/RLU.0000000000004860